化合物-42通过向RIPK3-介导的亡症来缓解急性损伤
Xiao-Yan He1, Fang Wang1,2, Xiao-Guo Suo1
1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, The Key Laboratory of Anti-inflammatory of Immune Medicines, Ministry of Education, Hefei, China.
British journal of pharmacology
|May 30, 2023
概括
一种新的RIPK3抑制剂,化合物42 (Cpd-42),通过阻断亡,有效地减少急性损伤 (AKI) 的损伤和炎症. 这种RIPK3抑制剂显示出作为AKI潜在治疗剂的前景.
科学领域:
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 由RIPK1,RIPK3和MLKL介导的亡,在急性损伤 (AKI) 中至关重要.
- 一种新型的RIPK3抑制剂,化合物42 (Cpd-42),已证明在缓解全身炎症方面具有有效性.
- 这项研究调查了CPD-42对AKI及其潜在机制的保护潜力.
研究的目的:
- 在急性损伤模型中评估CPD-42的保护作用.
- 阐明Cpd-42减轻AKI的分子机制.
- 评估CPD-42作为损伤潜在治疗剂的作用.
主要方法:
- 在体内研究使用西斯和缺血/再输血 (I/R) 诱导的AKI模型.
- 在体外研究中,使用西斯和低氧/再氧化 (H/R) 诱导的HK-2细胞损伤.
- 分子技术包括传输电子显微镜,RIPK3敲击细胞,分子对接和位点定向突变发生.
主要成果:
- 在实验室中,cpd-42显著降低了细胞损伤,亡和炎症.
- 在体内,Cpd-42治疗缓解了AKI,在西斯和I/R诱导模型中观察到.
- 通过在Thr94和Ser146形成键,Cpd-42直接抑制了RIPK3,阻断了RIPK3的酸化并减轻了AKI.
结论:
- 化合物42作为一种新的RIPK3抑制剂,减少损伤和AKI中的亡.
- Cpd-42的机制涉及与RIPK3的特定位点结合,从而抑制其功能.
- Cpd-42代表了治疗急性损伤的有希望的治疗候选者.
相关概念视频
01:29Acute Kidney Injury II: Pathophysiology
37
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
37
01:22Acute Kidney Injury I: Introduction
39
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
39
01:20Acute Kidney Injury V: Interprofessional Care
30
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
30
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
41
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
41
01:16Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
01:29Acute Kidney Injury III: Clinical Manifestations
45
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
45